Latest Breaking News On - Alanh auerbach - Page 4 : vimarsana.com

Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Puma Biotechnology, Inc. , a biopharmaceutical company , announced the design of the Phase II trial of alisertib for the treatment of patients with HER2-negative, hormone receptor-positive metastatic.

United statesCalvin wongAlanh auerbachDrug administrationExchange commissionPuma biotechnology incEuropean commissionPuma biotechnologyChief scientific officerChief executive officerAnnual report

Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
financialpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialpost.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesNorth vancouverBritish columbiaCalvin wongGabriel friedmanAlanh auerbachOlipriya dasBarbara shecterJoe oconnorDrug administrationPuma biotechnology incEuropean commissionPostmedia network incExchange commissionNational post

Puma Biotechnology Reports Third Quarter 2023 Financial Results

LOS ANGELES (BUSINESS WIRE) Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2023. Unless otherwise stated, all comparisons are for the third quarter of 2023 compared to the third quarter of 2022.Product revenue, net consist.

United statesAlanh auerbachDrug administrationPuma biotechnology incExchange commissionDevelopment expensesEuropean commissionPuma biotechnologyChief executive officerOrphan drug designationFull yearBiotechnology conference callPuma patient lynxFetal toxicityFull prescribing informationAnnual report

Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting

Puma Biotechnology, Inc. , a biopharmaceutical company, announced the poster presentation of a Phase I/II trial of alisertib plus pembrolizumab for the treatment of patients with Rb-deficient head.

United statesAlanh auerbachFayem johnsonEuropean commissionPuma biotechnology incUniversity of texas md anderson cancer centerDrug administrationInternational conference on molecularDivision of cancer medicineDepartment of thoracic head neck medical oncologyPuma biotechnologyMolecular targetsCancer therapeuticsNeck medical oncologyCancer medicineCancer center

Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembr

LOS ANGELES (BUSINESS WIRE) Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the poster presentation of a Phase I/II trial of alisertib plus pembrolizumab for the treatment of patients with Rb-deficient head and neck squamous cell carcinoma (Clinicaltrials.gov identifier NCT04555837).

United statesAlanh auerbachFayem johnsonDrug administrationDivision of cancer medicineDepartment of thoracic head neck medical oncologyUniversity of texas md anderson cancer centerPuma biotechnology incInternational conference on molecularEuropean commissionPuma biotechnologyMolecular targetsCancer therapeuticsNeck medical oncologyCancer medicineCancer center